Conference · Philadelphia, Pennsylvania
Annual Oncology Market Access & Pricing USA
Advertising, Marketing · Pharmaceuticals
Key numbers
- Editions on record
- 1first in 2017
About Annual Oncology Market Access & Pricing USA
Co-chaired by Aetna's Michael Kolodziej, the 2016 conference was seen as the most targeted and high-level gathering on commercialization of cancer products in the US. Join 150+ senior executives attended, including the following leading oncology innovators: Celgene;Eisai; Janssen; Novartis; BMS; Lilly; Genentech; Baxalta; GSK and Takeda. Here's why you should attend: Value-Based Pricing Metrics Round Robin - Hear why payers are hungry for these models, how they may leverage them, and which metrics will make a significant impact on the market access environment Determine How to Best Position Your Brand in an Evolving Market - Work cross-functionally with teams to address the challenges these metrics bring to develop a stronger market access trajectory by better demonstrating your products' importance. Prepare for Stakeholder's Demands - Adopt new business strategies that effectively generate, manage, and apply relevant health economic and clinical data from drug development through reimbursement Set Your Brand Apart in the Changing Payment Model Landscape - Decipher how potential APMs may impact your products and determine which are likely to have significant risks for the adoption of innovative drugs and biologics
From our listing of this edition. Details may have changed since.
Editions
| Year | Dates | Where | Exhibitors | Visitors |
|---|---|---|---|---|
| 2017 | 15–16 Jun 2017 | Le Meridien Philadelphia Philadelphia, Pennsylvania | — | — |
Past editions from the bvents archive (2008–2019) and organiser figures where they were published.
Questions
When is Annual Oncology Market Access & Pricing USA?
The next dates haven't been confirmed. The last edition we have on record was 15–16 Jun 2017.
Where is it held?
The last edition we have was at Le Meridien Philadelphia, Philadelphia, Pennsylvania.